Merrell Dow Pharmaceuticals

Merrell Pharmaceuticals, Inc.

Aventis Pharmaceuticals Inc.

Richardson-merrell Inc.

Hoechst Marion Roussel

Aventis Pharma Limited

James R. Mccarthy

Michael L. Edwards

Donald P. Matthews

Michael L Edwards

James R McCarthy

David M Stemerick

Ronald E Bambury

Timothy A Gillespy

Laird F Miller

Donald Paul Matthews

Tahir Nadeem Majid

Paul Joseph Cox

Shelley Amendola

Brian L Pedgrift

Christopher D Edlin

Andrew David Morley

Herve Bouchard

Stephanie Deprets

Charles J Gardner

Ronald D Snyder

Alan J Bitonti

Roger A Parker

Frank Halley

Sai P Sunkara

Nellikunja J Prakash

Mark T Yates

Esa T Jarvi

Mark J Vaal

Kim S Chen

James R Mccarthy

John G Jurcak

Didier Babin

John Charles Reader

Dominique Damour

Conception Nemecek

Paul S Wright

Matthieu Barrague

Francois Clerc

Michael Cherry

Ramalinga M Dharanipragada

Kwon Yon Musick

Chantal Carrez

Dorothea Kominos

Steven J Busch

Nawaz Mohammed Khan

Justine Yeun Quai Lai

Laurence Gauzy

Olivier Houille

Alain Le-Brun

Lloyd J Payne

James E Matt

Daniel N A Bezard

Yan Du

Philippe Bey

Philip M Weintraub

Albert Sjoerdsma

Terry L Bowlin

David John Aldous

Iain M McLay

Bernard Baudoin

Keith A Diekema

Robert J Dinerstein

Peter P McCann

Ashfaq Ahmad Parkar

Ashfaq Ahmed Parkar

Harry W Ritter

Phillip Marvin Weintraub

Stephanie D Deprets

James E Matt, Jr

Peter P Mccann

The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Benzimidazoles

The invention is directed to physiologically active compounds of general formula (I):&#x2014; and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles for inhibiting aurora2 and other kinases

Thienopyrazoles of formula I, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK). 

Thienopyrazoles

Compounds of the formula and N-oxides, prodrugs, acid bioisosteres, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisosteres of such salts or solvates, to compositions comprising such compounds, and methods of treatment comprising administering, to a patient in need thereof, such compounds and compositions.

Pyrrolopyrimidines

The invention is directed to physiologically active compounds of general formula (I):and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles

The invention is directed to physiologically active compounds of the general formula (Ix)and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

This invention relates to the compounds of 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)methyloxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxyphenylsilyl)methyloxy]phenol, polymorphs thereof and their pharmaceutically acceptable salts, useful as antiatherosclerotic agents.

2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and

The present invention provides compounds of the formula ##STR1## wherein R is hydrogen or --C(O)--(CH.sub.2).sub.m --Q wherein Q is hydrogen or --COOH and m is an integer 1, 2, 3 or 4;

Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant

The present invention relates to polyamine derivatives of the formula RHN-(CH.sub.2).sub.m -NH-(CH.sub.2).sub.n -NHR wherein m is an integer from 2 to 4, n is an integer from 3 to 10 and R is C.sub.2 -C.sub.6 alkyl or --(CH.sub.2).sub.p -Ar wherein Ar is phenyl or naphthyl and p is an integer from 0 to 2; and the pharmaceutically acceptable addition salts thereof which are useful as radioprotective agents. It relates also to the use of polyamines of the formula RHN-(CH.sub.2).sub.m -NH-(CH.sub.2).sub.n -NH-(CH.sub.2).sub.m -NHR wherein m is an integer from 2 to 4, n is an integer from 3 to 10 and R is C.sub.2 -C.sub.6 alkyl or --(CH.sub.2).sub.p -Ar wherein Ar is phenyl or naphthyl and p is an integer from 0 to 2; and the pharmaceutically acceptable addition salts thereof as radioprotective agents.

Polyamine derivatives as radioprotective agents

This invention relates to certain novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives, and compositions thereof, which are useful in the treatment of patients afflicted with neoplastic or viral disease states.

2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and

2'-halomethylidene, 2'-ethenylidene and 2'-ethynl cytidine, uridine and

This invention relates to certain polyamine derivatives, to the methods and intermediates useful for their preparation, and to their use in treating diseases caused by infestation with a variety of parasitic protozoa.

Polyamine derivatives

The present invention relates to a method for the treatment of patients suffering from certain neoplastic disease states which comprises administering a therapeutically effective amount of a compound of the formula: ##STR1## wherein m is an integer 6 to 9, Z is a saturated (C.sub.2 -C.sub.6) alkylene moiety, each R group independently is hydrogen, methyl, ethyl, or n-propyl except that both R groups cannot be hydrogen when Z is a straight chain; or a pharmaceutically acceptable acid addition salt thereof. Said treatment can optionally comprise conjunctive therapy with a polyamine oxidase inhibitor. The invention also relates to certain novel polyamine derivatives.

Polyamine derivatives as antineoplastic agents

2-'-ethenylidene cytidine, uridine and guanosine derivatives

Growing community of inventors

Cincinnati, OH, United States of America

Michael L Edwards